ELAN — Elanco Animal Health Inc

NYSE · Health Care · Pharmaceuticals · CIK 1739104 ·
Last close
$24.50
Market Cap
$12.24B
52W High
$26.29
52W Low
$19.40
ADV30
6,919,971
Next earnings
2026-08-06
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,371,000,000 785,000,000 169,000,000 57,000,000 13,222,000,000 428,000,000 6,722,000,000
Dec 2025 1,144,000,000 589,000,000 19,000,000 -276,000,000 13,358,000,000 545,000,000 6,811,000,000
Sep 2025 1,137,000,000 607,000,000 27,000,000 -34,000,000 13,551,000,000 505,000,000 6,802,000,000
Jun 2025 1,241,000,000 713,000,000 85,000,000 11,000,000 13,742,000,000 539,000,000 6,967,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$577,000,000
Investing CF
$-281,000,000
Financing CF
$-392,000,000
CapEx
$-262,000,000
Dividends Paid
Buybacks
$-47,000,000
EPS Diluted TTM
$-0.50
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,125,000,000
Inventory
$1,717,000,000
Receivables
$1,154,000,000
ST Investments
EBIT TTM
$40,000,000
Pretax Income TTM
$-197,000,000
Interest Exp TTM
$237,000,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,893,000,192
EBITDA
$970,000,000
Free Cash Flow
$692,124,992
Enterprise Value
$16,108,514,304
Total Cash
$428,000,000
Total Debt
$4,300,000,256
Shares Out
499,449,583
Trailing EPS
$-0.50
Book Value
$13.02
ROE
-3.8%
ROA
1.5%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 4,715,000,000 252,000,000 -232,000,000 13,358,000,000 6,811,000,000 560,000,000
Dec 2024 4,439,000,000 251,000,000 338,000,000 12,614,000,000 6,518,000,000 541,000,000
Dec 2023 4,417,000,000 326,000,000 -1,231,000,000 14,362,000,000 8,139,000,000 271,000,000
Dec 2022 4,411,000,000 384,000,000 -78,000,000 15,491,000,000 8,202,000,000 452,000,000

TTM Snapshot

Revenues TTM
$4,255,000,000
NetIncome TTM
$-901,000,000
OpCashFlow TTM
$0
Assets (Latest)
$12,614,000,000
Forward EPS
$1.19

Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $23.00 · spot: $24.50 · call volume: 202 · put volume: 86

Peers — same industry

TickerNameMarket CapLastDaily %
IONS IONIS PHARMACEUTICALS INC $12.33B $74.58
AXSM Axsome Therapeutics, Inc. $12.64B $245.64
ASND Ascendis Pharma A/S $13.17B $213.23
BBIO BridgeBio Pharma, Inc. $13.26B $67.68
BMRN BIOMARIN PHARMACEUTICAL INC $11.19B $57.91

News headlines (Yahoo Finance, 1h cache)

Is It Too Late To Consider Elanco Animal Health (ELAN) After Its Strong 1 Year Rally?
2026-06-05 06:07 · Yahoo
Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick
2026-06-04 21:30 · Yahoo
A Flesh-Eating Fly Adds to the Beef Industry’s List of Problems
2026-06-04 20:21 · Yahoo
Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm
2026-06-04 16:15 · Yahoo
New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience
2026-06-03 11:26 · Yahoo
A Look At Elanco (ELAN) Valuation After Early Befrena Launch And Renewed Investor Optimism
2026-06-01 21:14 · Yahoo
3 of Wall Street’s Favorite Stocks We Think Twice About
2026-06-01 19:20 · Yahoo
Elanco (ELAN) Is Up 9.8% After Launching Befrena, Its Second USDA-Approved Pet Biologic
2026-06-01 18:12 · Yahoo
3 Healthcare Stocks We Keep Off Our Radar
2026-05-28 16:30 · Yahoo
Monumental Public-Private Initiative Forms to Permanently Close America's Protein Gap
2026-05-27 16:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.